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Summary
PRINCIPLES: Cardiac myxoma is the most commonly
diagnosed cardiac tumour. Infection of herpes simplex vir-
us 1 (HSV1) has been postulated to be a factor for this
pathologic entity. The aim of the current study was to eval-
uate the association between HSV 1 and myxoma occur-
rence.
METHODS: Between 1965 and 2005, 70 patients (36 fe-
male, mean age: 52.6 years) underwent a resection of myx-
oma. Selected variables such as hospital mortality and mor-
bidity were studied. A follow-up (FU; mean FU time: 138
± 83 months) was obtained (76% complete). Immunohis-
tological studies with monoclonal antibodies against HSV
type 1 were performed on tumour biopsies of 40 patients.
RESULTS: The mean age was 53 ± 16 years (range 23 to
84 years, 51% female). Of the investigated population, 31
(44%) were in New York Heart Association (NYHA) class
III-IV. Mitral valve stenosis was identified in 14 patients
(20%), and in 25 (36%) patients mitral valve was insuffi-
cient.
During hospitalisation 3 patients suffered from a transient
neurological disorder, and in addition to myxoma resection
18 (25.7%) patients had to undergo an additional interven-
tion. The overall survival rate was 91% at 40 years. There
was no early postoperative mortality in follow-up, although
4 patients died and 2 patients had been re-operated on for
recurrent myxomas after 2 and 9 years. Immunohistology
revealed no positive signals for HSV-1 antigens among the
40 analysed cases.
CONCLUSION: Complete surgical resection, septum in-
cluded, was the treatment of choice and mandatory to pre-
vent relapse. Peri-operative morbidity and mortality over
40 years remained low, and no association between HSV
infection and occurrence of cardiac myxoma was found.
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Introduction
Primary tumour of the heart is a rare entity with incidence
ranging between 0.00071 and 0.0029% of unselected pa-
tient autopsies [1]. Approximately 80% of the tumours are
benign and nearly half of these are myxomes [2]. It seems
that intracardiac myxoma is a frequent pathology which
may be found in the left atrium in 80% of cases, 7 to 20%
are found in the right atrium, and the remaining 10% are
diagnosed either in the left or right ventricle [3]. Currently,
the broadly accepted therapy modality is surgical excision
with very low overall mortality of up to 3%. Although the
therapy, as well the ante mortem diagnosis, of this patho-
logical entity seems to be very successful, the underlying
cause remains unclear. Familial cardiac myxomas which
represent less than 10% of all myxomas are related to the
Carney complex, a multiple neoplasia and lentiginosis syn-
drome. The sporadic tumours which represent a majority
of this pathology do not have a clearly defined patholo-
gical cause. Chronic infection related to the HSV 1 infec-
tion has been suggested to be a potential factor that may
provoke generation of myxoma. It is true that inflammat-
ory symptoms are present in about half of the patients with
a diagnosis of myxoma, including fatigue, fever, weight
loss and laboratory abnormalities (elevation of leukocyte
count, IL6, erythrocyte sedimentation rate, and serum C-re-
active protein). Further immunohistological investigations
have supported this theory and it has been shown that atrial
myxoma may arise via a reactive process induced by HSV
1.
Herein we evaluated immunohistological patterns of 40
consecutive patients to determine if HSV 1 infection of the
extracted myxomas was present. Additionally, our experi-
ence from over 40 years of follow-ups, including treatment
modalities and long-term results, in 70 cardiac myxoma pa-
tients are reported.
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Methods
Patient characteristics
From January 1965 to January 2005, 70 consecutive pa-
tients were operated on for the removal of primary intrac-
ardiac myxoma at the University Hospital Zurich. Of these,
36 were female (51%) and 34 (49%) were male. The mean
age at time of the interventions was 53 ± 16 years (range
23 to 84 years). The methods used to confirm the diagnos-
is of a cardiac myxoma varied over the four decades. In
the earlier years, 2 patients were diagnosed by cardiac cath-
eterisation. More recently, transthoracic echocardiography
(TTE) was performed on 40 patients and transesophageal
echocardiography (TEE) was performed on 28 patients.
The correct diagnosis was made in every case. Myxomas
were identified in 62 patients in the left atrium (89%) and
8 in the right atrium (11%). Swiss Carney syndrome was
identified in 4 (6%) cases (table 1).
The most frequently observed symptoms were associated
with congestive cardiac heart failure symptoms, and 31 pa-
tients were in class NYHA III/IV. Congestive heart failure
was associated with mitral valve obstruction in 14 (20%)
and with insufficiency in 25 (36%) patients (table 2). The
myxom were the source of peripheral emboli in 6 (9%) pa-
tients and 18 (26%) patients suffered a stroke. In addition,
constitutional symptoms and signs of a generalised disease
with fever were reported in 16 (23%) patients.
Operative technique
The tumour was excised under cardiopulmonary bypass
using aortic and bicaval cannulation. Cardiac arrest with
moderate hypothermia (26–28 °C) was used in 44 (63%)
of the patients. Myocardial protection was achieved by ret-
rograde blood cardioplegia. Repetitive dosage was given
every 10 minutes.
In 26 (37%) patients, the operation was performed in nor-
motermia (36 °C) without cardiac arrest in ventricular fib-
rillation. In both surgical modalities, the left ventricle was
vented via the left superior pulmonary vein.
Immunohistological studies
Myxoma samples were fixed in 10% neutral formalin and
embedded in paraffin for histological examination. The
presence of both myxoid stroma and myxoma cells in tissue
sections stained with haematoxylin and eosin (H&E) was
diagnostic of atrial myxoma. A monoclonal antibody
(Mab) prepared using HSV 1 strain Stoker as an antigen
was supplied by Vector Lab Ltd (Newcastle, UK). This
technique has been published previously [4], and for details
see also Li et al. (Am J Pathol 2003, 163:2407–2412).
Follow-up
All patients had follow ups at regular intervals. They un-
derwent clinical examination, roentgenography, electrocar-
diography and echocardiography. Transthoracic echocardi-
ography was performed routinely prior to discharge and
then subsequently every year. Follow-up of the survivors
was accomplished by means of questionnaires and tele-
phone calls.
Results
Complete excision of the tumour with a cuff of atrial tissue
was the basic principle of excision and was successful in
all patients. The surgically created atrial septal defect was
either closed directly for 59 (84%) patients or repaired in
11 (16%) patients by using an autologous pericard patch
or Dacron patch (C.R. Bard, Inc., Haverhill, MA). Coron-
ary bypass was performed in 12 (17%) patients, the mitral
valve was reconstructed with annuloplasty and quadrangu-
lar resection in 3 (4%) patients, and the tricuspid valve was
reconstructed in 2 (3%) patients (De Vega reconstruction).
Implantation of the aortic and of the pulmonary valve was
performed in 1 (1.5%) patient. The mean time of extracor-
poreal circulation was 71 ± 38 minutes. Surgical revision
in the first 48 hours was performed in 3 (4%) patients,
which was because of acute haemorrhage and pericardial
tamponad. Surgical revision after 48 hours was performed
in 2 patients; in one because of insufficient mitral valve re-
construction, and in the second patient because of late re-
active pericardial tamponad. The mean intensive care unit
(ICU) stay was 32 ± 17 hours, patients were extubated
after 9 ± 5 hours (range between 3 and 24 hours), and mean
hospital stay was 10 ± 3 days (range 4 to 17 days) (table
3). There was no in-hospital mortality. During hospitalisa-
tion, 2 (3%) cases of pneumonia and one case of superfi-
cial wound infections were diagnosed. In all cases, therapy
was conservative. One patient developed embolism of the
femoral artery. The source of the embolism was a thrombus
in the left ventricle, which was ascertained by histological
examination. Three cases (7%) had transient neurological
events (table 3).
The follow-up period after resection of a myxoma ranged
between 46 and 340 months (mean 138 ± 83 months). From
the follow-up, 6 patients were excluded as at the time of
the study they had no residency address in Switzerland. Of
64 questionnaires, 46 (72%) were returned and evaluated.
The mean age at the time of evaluation was 70 ± 16 years.
The overall survival rate was 91% at 40 years, and 4 (9%)
Table 1: Preoperative characteristics of the patients.
Patients profile No of patients (N = 70)
Male gender 34 (49%)
Female gender 36 (51%)
Mean age ± SD (years) 53 ± 16
Myxoma in right atrium 8 (11%)
Myxoma in left atrium 62 (89%)
Swiss Carney syndrome 4 (6%)
Table 2: Clinical symptoms in 70 patients with intracardiac myxoma.
Symptoms No. of patients
Cardiac
Dyspnea (NYHA III or IV) 31 (44%)
Mitral regurgitation 25 (36%)
Mitral stenose 14 (20%)
Palpitation 11 (16%)
Embolic
Central nervous system 18 (26%)
Peripheral 6 (9%)
Constitutional
Fever 16 (23%)
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patients died where the cause of death was not of cardiac
origin.
One sporadic myxoma recurred, which was related to in-
sufficient excision. Additionally, 1 of the 4 patients with fa-
milial myxoma had a recurrence. This patient was re-oper-
ated on three times in a period between 1986 and 1995.
In the long-term follow-up, 43 patients (95%) were sub-
jectively asymptomatic and had no postoperative complica-
tions. Two patients (4%) reported cardiac symptoms. In the
early postoperative period, 10 patients developed atrial fib-
rillation, however at discharge all were converted into sinus
rhythm. In the long-term follow-up, two patients developed
chronic atrial fibrillations and were treated with warfarine.
No thrombo-embolic event or stroke was observed follow-
ing discharge (table 4).
Pathology results
In all 70 specimens, the diagnosis of myxoma was verified
by histological examination. After the tumours were resec-
ted, the tissue was fixed in 10% formaldehyde. The histolo-
gical specimens were stained with haematoxylin and eosin.
Additionally, immunohistology of HSV 1 and 2 was per-
formed on 40 specimens. The material for this investigation
was gathered retrospectively from a pathology tissue bank.
Tumours extracted between 1965 and 1982 were not
stored, so only 40 cases were evaluated for HSV 1 presen-
ce. In all 40 cases there was no validation of HSV 1 infec-
tion.
Discussion
Myxomas are the most frequent benign primary tumours
of the heart and they represent approximately 0.3% of all
open-heart surgeries reported in the literature [5, 6]. The
Table 3: Peri-operative evolution of the patients.
Peri-operative data No. of patients
Successful Tumour resection 70 (100%)
Ventricular fibrillation 26 (37%)
Cardiac arrest 44 (63%)
Closure of the septum with patch 11 (16%)
Coronary bypass graft 12 (17%)
Mitral valve reconstruction 3 (4%)
Tricuspid valve reconstruction 2 (3%)
Superficial wound infection 2 (3%)
Pulmonary valve replacement 1 (1.5%)
Aortic valve replacement 1 (1.5%)
Transient neurological events 3 (7%)
Peripheral embolisation 1 (2%)
Hospitalisation time ± SD (Days) 10 ± 3
In Hospital mortality 0
Table 4: Follow up in 46 patients after the myxoma resection.
Follow up No. of patients
Mean age at follow up ± SD
(years)
70 ± 16
Mean time after intervention ± SD
(Months)
138 ± 83
Mortality during follow-up 4 (9%)
Recurrent myxoma 2 (4%)
Chronic atrial fibrillation 2 (4%)
Diagnosed HSV (serological
diagnosis)
0
first case of intracavitary myxoma was described in 1854
and, until 1951, the diagnosis of cardiac tumour was de-
duced in post-mortem investigations. The introduction of
echocardiography definitively facilitated the diagnosis, and
to-date remains the most important modality for imaging
of cardiac tumours. This non-invasive technique allows ad-
equate identification of tumour size, position, mobility and
location [7].
The therapy of choice, after establishing diagnosis, is sur-
gical excision. This has to be performed as soon as possible
because of the risk of valvular obstruction and/or systemic
embolisation [8]. It appears that good visualisation of all
four chambers is an indication of successful surgical treat-
ment. From such visualisation, additional tumours may ap-
pear which were not identified during the preoperative
work up [9]. As such, a bi-atrial approach has previously
been advocated [10]. In our series, in the first two decades
we also performed the proposed bilateral exposure in order
to evaluate the left and right cardiac chambers. However,
with the use of intraoperative transesophagial echocardio-
graphy we focused on the target chambers, with exposure
of ventricular and atrial chambers on the corresponding
side.
Although the diagnosis and the treatment strategies in this
pathological entity seem to be well established with very
low mortality (ranging between 0 and 3%), the origin of
myxomas is not clearly defined. In most cases, myxomas
are diagnosed as sporadic tumours, and about 10% of cases
are familial and are transmitted in an autosomal dominant
way [11, 12]. Familial myxomas are presented as a com-
ponent of a Carney syndrome [13]. In Carney syndrome,
the mutation of the PRKAR1alpha gene, encoding the
R1alpha regulatory sub-unit of cyclic-Amp-dependent pro-
tein kinase A, is responsible for complex symptomatic and
manifestation [14]. Compared to the sporadic myxomas,
the familial cardiac myxomas may have multiple intracar-
diac locations with a recurrence rate of about 22%, whereas
the recurrence rate of sporadic tumours is at 3–4% (15). In
our series, 4 patients with Carney syndrome were operated
on successfully and only 1 (25%) patient had recurrences,
being re-operated on three times in a period of 9 years.
Although the pathogenesis of familiar myxomas is well
defined, the pathogenesis of sporadic myxomas remains
unknown. In the past, because of abundant expression of
mucopolysaccharidic matrix in tumour stroma, extensive
expression of mucin gen was suggested as a potential factor
for tumour generation [16]. However, clinical implications
of mucin gens in cardiac myxomas have never been as-
sessed.
Additionally, it has been postulated that the origin of dis-
ease might be in relation to HSV 1 infection. In a series of
17 patients being operated on for myxoma resection, Li et
al. were able to find the presence of the HSV 1 antigen in
12 (70%) patients, and in 8 (30%) cases the DNA of HSV
1 was identified [7]. In our series, tumour diagnosis of be-
nign myxoma was confirmed in all 40 investigated cases.
Using the immunohistology method that was described by
Li et al. [7], we were unable to confirm the presence of
the HSV1 antigen. Furthermore, according to the question-
naires and telephone conversations to the personal physi-
cians, none of the 40 investigated cases had either a clinical
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or serological suspicion of HSV 1 infection. Thus our res-
ults cannot confirm that HSV 1 is responsible for myxoma
generation.
We have to be aware that HSV 1 infection is very common
in an adult sexually active population and that its preval-
ence has a growing tendency with age. The prevalence in
a non-high-risk middle-age population, ranges between 40
and 60% and reaches its plateau after 30 years. On the oth-
er hand, prevalence in high-risk groups may reach up to
90% and is often combined with HIV infections [17]. This
demographic data would suggest that if HSV 1 is respons-
ible for myxoma development, the prevalence, especially
in patients with a compromised immune system, would
definitively be higher than the observed 0.002%. Accord-
ing to data presented in this retrospective study, the theory
of HSV 1 infection as a factor cannot be supported from
either a diagnostic or epidemiological point of view. In this
context, we believe further pathological as well epidemi-
ological investigations have to be performed.
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